Min-Hwa Jasmine Lin

发表

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Prediction of Vss from In Vitro Tissue-Binding Studies

Zhiyang Zhao, Jonathan Roberts, L. Berry, 2010, Drug Metabolism and Disposition.

Corrigendum to “Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors” [Bioorg. Med. Chem. Lett. 19 (2009) 6307]

Kavita Shah, April Chen, David Bauer, 2010 .

Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds

April Chen, L. Berry, Liyue Huang, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

from in vitro Metabolic Intrinsic Clearance

April Chen, L. Berry, Liyue Huang, 2009 .

Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats

Liyue Huang, Min-Hwa Jasmine Lin, Jonathan Roberts, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics.

Kristin L. Andrews, B. Herberich, B. Moyer, 2019, ACS chemical biology.

Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1.7 Inhibitory GpTx-1 Peptide-Antibody Conjugates.

K. Gunasekaran, Hantao Liu, B. Herberich, 2017, ACS chemical biology.

In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

L. Berry, Liyue Huang, Min-Hwa Jasmine Lin, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of Tarantula Venom-Derived NaV1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis.

Dong Liu, Kristin L. Andrews, Zhulun Wang, 2018, Journal of medicinal chemistry.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2017, Journal of Medicinal Chemistry.

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

T. Bush, Grace Chung, R. Radinsky, 2015, Journal of Medicinal Chemistry.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Roman Shimanovich, Angel Guzman-Perez, R. Fremeau, 2017, Journal of medicinal chemistry.

Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC50 Shift

L. Berry, Min-Hwa Jasmine Lin, Zhiyang Zhao, 2013, Drug Metabolism and Disposition.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

K. Rex, A. Coxon, D. Whittington, 2016, Journal of medicinal chemistry.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2015, Journal of medicinal chemistry.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance

April Chen, L. Berry, Liyue Huang, 2010, Drug Metabolism and Disposition.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2016, ACS medicinal chemistry letters.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.